

EST AVAILABLE COPY

Specific gabapentin binding (cpm)




FIG. 3

R217A WILD TYPE Mice (N = 7)

Vehicle Pregabalin

Treatment (100 mg/kg PO @ - 120 min)

p < 0.05 (t-test: relative to vehicle-treated controls)

FIG. 4B

R217A WILD TYPE Mice (N = 7)

Time spent licking (seconds)

Time spent licking (seconds)

100

*

50

0

200 |-

Early Phase (0-10 min)


150

p < 0.05 (t-test: relative to vehicle-treated controls)

Treatment (100 mg/kg PO @ - 120 min)

-IG. 4C

R217A HETEROZYGOTE Mice (N = 7-8)




p <0.05 (t-test: relative to vehicle-treated controls)

Treatment (100 mg/kg PO @ - 120 min)

FIG. 4D

R217A HETEROZYGOTE Mice (N = 7-8)



p <0.05 (t-test: relative to vehicle-treated controls)

Treatment (100 mg/kg PO @ - 120 min)

R217A HOMOZYGOTE Mice (N = 7)

200 |-

Early Phase (0-10 min)

Time spent licking (seconds)

Time spent licking (seconds)

100

50

0

Vehicle

Pregabalin

150 |

150 125 100

no significant differences between Vehicle

no significant differences between Vehicle

and PGB-treated groups

Treatment (100 mg/kg PO @ - 120 min)

R217A HOMOZYGOTE Mice (N = 7)

250

(11-45 min) Late Phase

Vehicle

Pregabalin

and PGB-treated groups

Treatment (100 mg/kg PO @ - 120 min)




FIG. 6

	-	
	2	R217A
	ω	· .
	<u> </u>	
•.	2	TW
	ω	
	CT	
Ω	•	

BEST AVAILABLE COPY

+

FIG. 7A




FIG. 7B




FIG. 8A




FIG. 8B

